Citations

Mayo Clinic

Clear

2251 citation(s) found for "La, Lisa".

Defining a Link with Asthma in Mice Congenitally Deficient in Eosinophils
Lee, James J. , Dimina, Dawn, Macias, MiMi P., Ochkur, Sergei I. , McGarry, Michael P. , O'Neill, K.R. , Protheroe, Cheryl, Pero, Ralph, Cormier, Stephania A. , Lenkiewicz, Elizabeth, Colbert, Dana, Ackerman, Steven J. , Irvin, Charles G. , Lee, Nancy A., Nguyen, Duc Thanh , Rinaldi, Lisa

Science | September 16, 2004 | Volume: 305 | Issue: 5691 | Pages: 1773-1776

10.1126/science.1099472 | PMID 15375267 Get It

Eosinophils are often dominant inflammatory cells present in the lungs of asthma patients. Nonetheless, the role of these leukocytes remains poorly understood. We have created a transgenic line of mice (PHIL) that are specifically devoid of eosinophils, but otherwise have a full complement of hematopoietically derived cells. Allergen challenge of PHIL mice demonstrated that eosinophils were required for pulmonary mucus accumulation and the airway hyperresponsiveness associated with asthma. The development of an eosinophil-less mouse now permits an unambiguous assessment of a number of human diseases that have been linked to this granulocyte, including allergic diseases, parasite infections, and tumorigenesis.
Brain Natriuretic Peptide Enhances Renal Actions of Furosemide and Suppresses Furosemide-Induced Aldosterone Activation in Experimental Heart Failure
Cataliotti, Alessandro , Boerrigter, Guido, Costello‐Boerrigter, Lisa C. , Schirger, John A., Tsuruda, Toshihiro , Heublein, Denise M., Chen, Horng H. , Malatino, Lorenzo , Burnett, John C.

Circulation | March 16, 2004 | Volume: 109 | Issue: 13 | Pages: 1680-1685

10.1161/01.cir.0000124064.00494.21 | PMID 15023890 Get It

Background— The renal actions of brain natriuretic peptide (BNP) in congestive heart failure (CHF) are associated with increased diuresis and natriuresis, preserved glomerular filtration rate (GFR), and lack of activation of the renin-angiotensin-aldosterone system (RAAS). In contrast, diuretic-induced natriuresis may be associated with reduced GFR and RAAS activation. The objective of this study was to test the hypothesis that exogenous BNP enhances the renal diuretic and natriuretic actions of furosemide (Fs) and retards the activation of aldosterone in a model of CHF. Methods and Results— CHF was produced in 2 groups of dogs by ventricular pacing. One group received continuous (90-minute) intravenous Fs (1 mg · kg −1 · h −1 ). A second group (Fs+BNP) received 45-minute intravenous coinfusion of Fs (1 mg · kg −1 · h −1 ) and low-dose (2 pmol · kg −1 · min −1 ) BNP followed by 45-minute coinfusion of Fs (1 mg · kg −1 · h −1 ) and high-dose (10 pmol · kg −1 · min −1 ) BNP. Fs increased urinary flow, but the effect of Fs+BNP was greater. Similarly, urinary sodium excretion was higher in the Fs+BNP group. Although GFR tended to decrease in the Fs group, it increased in the Fs+BNP group (35±3 to 56±4*) (* indicates P <0.05 versus baseline) ( P <0.0001 between groups). Plasma aldosterone increased with Fs (41±10 to 100±11* ng/dL) but was attenuated in the Fs+BNP group (44±11 to 54±9 ng/dL low-dose and to 47±7 ng/dL high-dose) ( P =0.0007 between groups). Conclusions— Fs+BNP has more profound diuretic and natriuretic responses than Fs alone and also increases GFR without activation of aldosterone. Coadministration of BNP and loop diuretic is effective in maximizing natriuresis and diuresis while preserving renal function and inhibiting activation of aldosterone.
Compartment Syndrome in Surgical Patients
Warner, Mary E. , LaMaster, Lisa M., Thoeming, Amy K., Marienau, Mary E. Shirk, Warner, Mark A.

Anesthesiology | November 10, 2003 | Volume: 94 | Issue: 4 | Pages: 705-708

10.1097/00000542-200104000-00026 | PMID 11379693 Get It

Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure
Boerrigter, Guido, Costello‐Boerrigter, Lisa C. , Cataliotti, Alessandro , Tsuruda, Toshihiro , Harty, Gail J., Lapp, Harald , Stasch, Johannes-Peter, Burnett, John C.

Circulation | February 12, 2003 | Volume: 107 | Issue: 5 | Pages: 686-689

10.1161/01.cir.0000055737.15443.f8 | PMID 12578869 Get It

Background— BAY 41-2272 is a recently introduced novel orally available agent that directly stimulates soluble guanylate cyclase (sGC) and sensitizes it to its physiological stimulator, nitric oxide. To date, its therapeutic actions in congestive heart failure (CHF) remain undefined. We characterized the cardiorenal actions of intravenous BAY 41-2272 in a canine model of CHF and compared it to nitroglycerin (NTG). Methods and Results— CHF was induced by rapid ventricular pacing for 10 days. Cardiorenal and humoral function were assessed at baseline and with administration of 2 doses of BAY 41-2272 (2 and 10 μg · kg −1 · min −1 ; n=8) or NTG (1 and 5 μg · kg −1 · min −1 ; n=6). Administration of 10 μg · kg −1 · min −1 BAY 41-2272 reduced mean arterial pressure (113±8 to 94±6 mm Hg; P <0.05), pulmonary artery pressure (29±2 to 25±2 mm Hg; P <0.05), and pulmonary capillary wedge pressure (25±2 to 20±2 mm Hg; P <0.05). Cardiac output (2.1±0.2 to 2.3±0.2 L/min; P <0.05) and renal blood flow (131±17 to 162±18 mL/min; P <0.05) increased. Glomerular filtration rate was maintained. There were no changes in plasma renin activity, angiotensin II, or aldosterone. NTG mediated similar hemodynamic changes and additionally decreased right atrial pressure and pulmonary vascular resistance. Conclusion— The new sGC stimulator BAY 41-2272 potently unloaded the heart, increased cardiac output, and preserved glomerular filtration rate without activation of the renin-angiotensin-aldosterone system in experimental CHF. These beneficial properties make direct sGC stimulation with BAY 41-2272 a promising new strategy for the treatment of cardiovascular diseases such as CHF.
Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix Metalloproteinases
Tsuruda, Toshihiro , Boerrigter, Guido, Huntley, Brenda K., Noser, Josh A., Cataliotti, Alessandro , Costello‐Boerrigter, Lisa C. , Chen, Horng H. , Burnett, John C.

Circulation Research | December 13, 2002 | Volume: 91 | Issue: 12 | Pages: 1127-1134

10.1161/01.res.0000046234.73401.70 | PMID 12480813 Get It

Cardiac fibroblasts (CFs) produce extracellular matrix proteins and participate in the remodeling of the heart. It is unknown if brain natriuretic peptide (BNP) is synthesized by CFs and if BNP participates in the regulation of extracellular matrix turnover. In this study, we examined the production of BNP in adult canine CFs and the role of BNP and its signaling system on collagen synthesis and on the activation of matrix metalloproteinases (MMPs). BNP mRNA was detected in CFs, and a specific radioimmunoassay demonstrated that BNP 1-32 was secreted into the media at a rate of 11.2±1.0 pg/10 5 cells per 48 hours (mean±SEM). The amount of BNP secretion was significantly ( P <0.01) augmented by 10 −7 mol/L tumor necrosis factor-α in a time-dependent manner. BNP significantly ( P <0.01) inhibited de novo collagen synthesis as assessed by [ 3 H]proline incorporation, whereas zymographic MMP-2 (gelatinase) abundance was significantly ( P <0.05) stimulated by BNP between 10 −7 and 10 −6 mol/L. In addition, protein expression of MMP-1, -2, and -3 and membranous type-1 MMP was significantly increased by 10 −6 mol/L BNP. The cGMP analogue 8-bromo-cGMP (10 −4 mol/L) mimicked the BNP effect, whereas inhibition of protein kinase G by KT5823 (10 −6 mol/L) significantly ( P <0.05) attenuated BNP-induced zymographic MMP-2 abundance. In summary, this study reports that BNP is present in cultured CFs and that BNP decreases collagen synthesis and increases MMPs via cGMP–protein kinase G signaling. These in vitro findings support a role for BNP as a regulator of myocardial structure via control of cardiac fibroblast function.
Tobacco Use Outcomes Among Patients With Lung Cancer Treated for Nicotine Dependence
Cox, Lisa Sanderson , Ebbert, Jon O. , Drews, Amanda A., Croghan, Gary A., Clark, Matthew M. , Wolter, Troy D., Decker, Paul A. , Hurt, R. Douglas , Patten, Christi A. , Decker, Paul A.

Journal of Clinical Oncology | October 1, 2002 | Volume: 20 | Issue: 16 | Pages: 3461-3469

10.1200/jco.2002.10.085 | PMID 12177107 Get It

PURPOSE: There is a current lack of consensus about the effectiveness of nicotine dependence treatment for cancer patients. This retrospective study examined the 6-month tobacco abstinence rate among lung cancer patients treated clinically for nicotine dependence. PATIENTS AND METHODS: A date-of-treatment matched case control design was used to compare lung cancer patients (201 lung cancer patients, 41% female) and nonlung cancer patients (201 controls, 45% female) treated in the Mayo Clinic Nicotine Dependence Center between 1988 and 2000. The intervention involves a brief consultation with a nicotine dependence counselor. A treatment plan individualized to the patient’s needs is then developed. The primary end point was the self-reported, 7-day point prevalence abstinence from tobacco at 6-month follow-up. RESULTS: At baseline, compared with the controls, the lung cancer patients were significantly older (P < .001), reported higher motivation to stop smoking (P = .003), and were at a higher stage of change (P = .002). The 6-month tobacco abstinence rate was 22% for the lung cancer patients compared with 14% of the control patients (P = .024). After adjusting for age, sex, baseline cigarettes smoked per day, and stage of change, no significant difference was detected between lung cancer patients and controls on the tobacco abstinence rate. CONCLUSION: The results suggest that nicotine dependence treatment is effective for patients with a diagnosis of lung cancer. The majority of lung cancer patients were motivated to stop smoking.
Differential Actions of Vasopeptidase Inhibition Versus Angiotensin-Converting Enzyme Inhibition on Diuretic Therapy in Experimental Congestive Heart Failure
Cataliotti, Alessandro , Boerrigter, Guido, Chen, Horng H. , Jougasaki, Michihisa , Costello, Lisa C., Tsuruda, Toshihiro , Lee, Shang-Chiun, Malatino, Lorenzo , Burnett, John C.

Circulation | July 28, 2002 | Volume: 105 | Issue: 5 | Pages: 639-644

10.1161/hc0502.102962 | PMID 11827932 Get It

Background — Omapatrilat (OMA), a vasopeptidase inhibitor, simultaneously inhibits angiotensin-converting enzyme (ACE) and neutral endopeptidase, which degrades vasodilatory factors (eg, ADM) and natriuretic peptides. Based on the beneficial cardiorenal and humoral properties of the natriuretic peptides, we hypothesized that an acute vasopeptidase inhibitor with or without diuretic would result in more favorable cardiorenal and hormonal actions than ACE inhibition plus diuretic (ACEI+D) in congestive heart failure. Methods and Results — We compared the actions of OMA alone and with diuretic (OMA+D) to ACEI+D in a model of pacing-induced congestive heart failure. OMA+D decreased pulmonary arterial and pulmonary capillary wedge pressures to a greater level than OMA alone or ACEI+D. Glomerular filtration rate was lower with ACEI+D than with either OMA group. Plasma renin activity and aldosterone immediately increased with ACEI+D, whereas OMA+D resulted in higher plasma renin activity and a delayed increase in aldosterone. OMA alone did not increase plasma renin activity and aldosterone, but resulted in a sustained increase in plasma adrenomedullin, with higher urinary atrial natriuretic peptide, adrenomedullin, and cGMP excretions than with ACEI+D. Conclusions — Acute administration of OMA with or without diuretic results in more favorable cardiorenal and humoral responses in experimental congestive heart failure than does ACEI+D. There is no acute activation of renin and aldosterone with OMA alone such as occurs with ACEI+D and OMA+D. Thus, OMA with or without a diuretic possesses beneficial cardiorenal and humoral actions comparable to those observed with ACEI+D that can be explained by potentiation of natriuretic peptides.
Serological Expression Cloning of Novel Immunoreactive Antigens of Babesia microti
Lodes, Michael J., Houghton, Raymond L., Bruinsma, Elizabeth S. , Mohamath, Raodoh, Reynolds, Lisa D., Benson, Darin R., Krause, Peter J. , Reed, Steven G. , Persing, David H.

Infection and Immunity | July 27, 2002 | Volume: 68 | Issue: 5 | Pages: 2783-2790

10.1128/iai.68.5.2783-2790.2000 | PMID 10768973 Get It

ABSTRACT Increased recognition of the prevalence of human babesiosis in the United States, together with rising concern about the potential for transmission of this infection by blood transfusion, has provided motivation to develop definitive serologic and molecular tests for the causative agent, Babesia microti . To develop more sensitive and specific assays for B. microti , we screened a genomic expression library with patient serum pools. This screening resulted in the identification of three classes of novel genes and an additional two novel, unrelated genes, which together encode a total of 17 unique B. microti antigens. The first class (BMN1-2 family) of genes encodes seven closely related antigens with a degenerate six-amino-acid repeat that shows limited homology to Plasmodium sp. merozoite and sporozoite surface antigens. A second class (BMN1-8 family) of genes encodes six related antigens, and the third class (BMN1-17 family) of genes encodes two related antigens. The two remaining genes code for novel and unrelated sequences. Among the three classes of antigens and remaining novel sequences, five were chosen to code for the most immunodominant antigens (BMN1-2, -9, -15, and -17 and MN-10). Western blot analysis with the resulting recombinant proteins indicated that these antigens were targets of humoral immune responses during B. microti infection in humans.
Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP
Lewis, Jada , Dickson, Dennis W. , Lin, Wen-Lang, Chisholm, Louise, Corral, Anthony, Yen, Shu‐Hui, Skipper, Lisa , Yager, Debra, Eckman, Chris, Hardy, John , Hutton, Mike, Jones, Graham L. , Sahara, Naruhiko , McGowan, Eileen , Dickson, Dennis W , Hardy, John

Science | July 27, 2002 | Volume: 293 | Issue: 5534 | Pages: 1487-1491

10.1126/science.1058189 | PMID 11520987 Get It

JNPL3 transgenic mice expressing a mutant tau protein, which develop neurofibrillary tangles and progressive motor disturbance, were crossed with Tg2576 transgenic mice expressing mutant β-amyloid precursor protein (APP), thus modulating the APP-Aβ (β-amyloid peptide) environment. The resulting double mutant (tau/APP) progeny and the Tg2576 parental strain developed Aβ deposits at the same age; however, relative to JNPL3 mice, the double mutants exhibited neurofibrillary tangle pathology that was substantially enhanced in the limbic system and olfactory cortex. These results indicate that either APP or Aβ influences the formation of neurofibrillary tangles. The interaction between Aβ and tau pathologies in these mice supports the hypothesis that a similar interaction occurs in Alzheimer's disease.
Nondiagnostic Thyroid Fine-Needle Aspiration Cytology: Management Dilemmas
Chow, Lisa S. , Gharib, Hossein, Goellner, John R., Heerden, Jon A. van

Thyroid | July 26, 2002 | Volume: 11 | Issue: 12 | Pages: 1147-1151

10.1089/10507250152740993 | PMID 12186502 Get It